Mereo BioPharma Group (LON:MPH) Reaches New 12-Month Low at $40.19

Mereo BioPharma Group PLC (LON:MPH) reached a new 52-week low on Friday . The stock traded as low as GBX 40.19 ($0.53) and last traded at GBX 41.50 ($0.54), with a volume of 8727 shares trading hands. The stock had previously closed at GBX 45.50 ($0.59).

The company has a quick ratio of 2.05, a current ratio of 2.13 and a debt-to-equity ratio of 65.56. The stock has a market cap of $40.65 million and a P/E ratio of -0.92. The company’s 50-day moving average is GBX 61.57.

In other news, insider Anders Ekblom purchased 46,700 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were bought at an average cost of GBX 109 ($1.42) per share, for a total transaction of £50,903 ($66,513.79). Also, insider Peter J. Fellner bought 30,000 shares of the company’s stock in a transaction on Monday, April 29th. The stock was bought at an average cost of GBX 128 ($1.67) per share, for a total transaction of £38,400 ($50,176.40).

Mereo BioPharma Group Company Profile (LON:MPH)

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

See Also: Why is a lock-up period needed for an IPO?

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit